Does influenza vaccination induce bullous pemphigoid? A report of four cases

Downs, A. M. R.; Lear, John T.; Bower, Chris; Kennedy, C. T. C.

doi:10.1046/j.1365-2133.1998.02097.x

Cited by 48 publications

(63 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a multitude of other adverse events temporally associated with TIV, some of which have been described in published reports or listed in product labeling, though causality is generally uncertain [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60]. Due to the vast accumulation of symptom codes and medical conditions in VAERS, and in order to concisely summarize and present highlights of the safety profile, we limited our review.…”

Section: Discussionmentioning

confidence: 99%

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi

Burwen

Dobardzic

et al. 2009

Vaccine

171

122

View full text Add to dashboard Cite

a b s t r a c tIn preparation for pandemic vaccine safety monitoring, we assessed adverse events reported to the Vaccine Adverse Event Reporting System following receipt of trivalent inactivated influenza vaccines among adults from 1990 through 2005. We calculated reporting rates for nonserious, serious, and neurological adverse events. We reviewed reports of recurrent events and deaths, as well as reports identified through advanced signal detection. The most frequently reported events were local reactions and systemic symptoms. Guillain-Barré syndrome was the most frequently reported serious event (0.70 reports per million vaccinations). Adverse event reporting rates have been reasonably constant over time. No new safety concerns emerged after our review of 15 years of post-licensure surveillance data. These findings provide useful information if pandemic vaccine is rapidly distributed and pre-licensure data are limited.Published by Elsevier Ltd. BackgroundInfluenza vaccines are the primary method for the control of influenza and its complications and the most widely used type of vaccine for adults in the United States (US). The US and much of the world is preparing for the use of pandemic influenza vaccines [1]. However, even with extensive planning, limited safety data will be available for these vaccines prior to use. Safety profile highlights of the seasonal trivalent inactivated influenza vaccines (TIV) can provide a background for interpretation of adverse events that can be anticipated if pandemic influenza vaccines must be employed in the future. In addition, special importance for TIV safety monitoring stems from the 1976-1977 influenza season, when a mass vaccination effort in the US against swine influenza was halted after the vaccines appeared to be associated with an elevated risk of Guillain-Barré syndrome (GBS) [2].Placebo-controlled trials among older and healthy young adults have demonstrated that TIV administration is not associated with an increased risk of systemic symptoms (e.g., fever, malaise, myalgia); the most frequent adverse effect following vaccination is pain at the injection site [3] including anaphylaxis can occur [3], but the latter is rare [4]. A pre-licensure study of the recently licensed H5N1 vaccine identified headache, malaise, and myalgia as the most frequent systemic symptoms but also identified these at similar rates among placebo recipients [5]. Clinical trials are generally not large enough to detect rare adverse events. Post-licensure safety data provide examples of adverse event experiences among a larger and more diverse population, and reporting of adverse events following receipt of seasonal TIV to the US Vaccine Adverse Event Reporting System (VAERS) is an important source of this information. We examined 15 years of VAERS data among adults aged ≥18 years to describe patterns of adverse events after seasonal vaccines and to identify possible safety concerns that might merit intensified monitoring or evaluation. Although pandemic influenza vaccines will differ fr...

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi

Burwen

Dobardzic

et al. 2009

Vaccine

171

122

View full text Add to dashboard Cite

show abstract

“…Interestingly, both adult and childhood BP have been reported in association with vaccination. [21][22][23] And those findings could also be explained by the "epitope spreading phenomenon." 24 In this phenomenon, the primary disease, such as ordinary BP, exposes the BMZ to the immune system, which responds by producing an array of autoantibodies against proteins of the exposed BMZ without being pathogenetic themselves.…”

Section: Commentmentioning

confidence: 97%

Childhood Bullous Pemphigoid

Pablo¹,

González-Enseñat²,

Vicente³

et al. 2007

Arch Dermatol

View full text Add to dashboard Cite

“…In the literature there are 19 papers reporting 37 patients experiencing skin adverse effects after an influenza vaccination [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. There are only 2 reports of a typical drug reaction after an influenza vaccination: a case of generalized bullous fixed drug eruption and a case of toxic epidermal necrolysis [6,13].…”

Section: Discussionmentioning

confidence: 99%

“…Cutaneous adverse effects consisting mainly of a local reaction with erythema, induration and pain at the vaccination site are rarely reported [4,5]. Rare cases of systemic reactions with cutaneous manifestations such as vasculitis or neutrophilic dermatosis have been observed [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. We describe the first case of CHP after H1N1 vaccination in a child and discuss the spectrum of cutaneous reactions to influenza vaccine.…”

Section: Introductionmentioning

confidence: 99%

Cytophagic Histiocytic Panniculitis after H1N1 Vaccination: A Case Report and Review of the Cutaneous Side Effects of Influenza Vaccines

et al. 2011

View full text Add to dashboard Cite

Cytophagic histiocytic panniculitis (CHP) is a rare disease mostly caused by viral infections and/or lymphoproliferative diseases. We describe a case of CHP associated with H1N1 vaccine during the winter 2009–2010 vaccination campaign and discuss the cutaneous side effects of influenza vaccines. A 6-year-old child presented with inflammatory subcutaneous nodules, which had appeared 1 month after the first injection of H1N1 vaccine and 1 week after the second injection. There was no history of recent infection. The skin lesions spontaneously disappeared without scarring. In CHP the abnormal cytokine secretion from neoplastic or reactive T cells promotes monocyte-macrophage activation and haemophagocytosis. Vaccination is not a common cause of CHP, but it seems possible that, as in infectious diseases, reactive T cells to the vaccine antigen could trigger CHP.

show abstract

Does influenza vaccination induce bullous pemphigoid? A report of four cases

Cited by 48 publications

References 5 publications

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Childhood Bullous Pemphigoid

Cytophagic Histiocytic Panniculitis after H1N1 Vaccination: A Case Report and Review of the Cutaneous Side Effects of Influenza Vaccines

Contact Info

Product

Resources

About